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Insights Into SND1 Oncogene
Promoter Regulation
Begoña Ochoa, Yolanda Chico and María José Martínez*
Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain
The staphylococcal nuclease and Tudor domain containing 1 gene (SND1), also known
as Tudor-SN, TSN or p100, encodes an evolutionarily conserved protein with invariant
domain composition. SND1 contains four repeated staphylococcal nuclease domains
and a single Tudor domain, which confer it endonuclease activity and extraordinary
capacity for interacting with nucleic acids, individual proteins and protein complexes.
Originally described as a transcriptional coactivator, SND1 plays fundamental roles in
the regulation of gene expression, including RNA splicing, interference, stability, and
editing, as well as in the regulation of protein and lipid homeostasis. Recently, SND1
has gained attention as a potential disease biomarker due to its positive correlation with
cancer progression and metastatic spread. Such functional diversity of SND1 marks this
gene as interesting for further analysis in relation with the multiple levels of regulation
of SND1 protein production. In this review, we summarize the SND1 genomic region
and promoter architecture, the set of transcription factors that can bind the proximal
promoter, and the evidence supporting transactivation of SND1 promoter by a number of
signal transduction pathways operating in different cell types and conditions. Unraveling
the mechanisms responsible for SND1 promoter regulation is of utmost interest to
decipher the SND1 contribution in the realm of both normal and abnormal physiology.
Keywords: staphylococcal nuclease and Tudor domain containing 1, Tudor-SN, transcriptional regulation,
chromosome 7 band 7q.32.1, miR-593, SND1-IT1, oncogene promoter
INTRODUCTION
Staphylococcal nuclease (SN) and Tudor domain containing 1 (SND1) gene encodes SND1, an
evolutionarily conserved multidomain protein also called Tudor-SN, TSN or p100 (1–4). The
invariant domain composition of SND1 comprises a tandem of four SN-like domains at the
N-terminus (SN1-4) followed by a C-terminal domain formed by a fusion of a Tudor domain and a
truncated SN domain (5) (Figure 1). The potent interaction capacity of SN domains with RNA (6)
and of the Tudor domain with modified (methylated) aminoacids (7, 8), together with its intrinsic
endonuclease activity (9) for degrading double-stranded RNA (10) enable SND1 for participating in
an unusual multiplicity of functions (summarized in Figure 1). We refer the reader to some recent
reviews addressing the biochemistry and function of this protein (11–13).
It has now become clear that the SND family members behave as global regulators of gene
expression. SND1 was first characterized as a transcriptional coactivator, interacting with several
Abbreviations: ATF, activating transcription factor; ER, endoplasmic reticulum; miRNA, microRNA; NF-κB, necrosis factor
κB; SND1, staphylococcal nuclease and tudor domain containing 1; SRE, sterol response element; SREBP, SRE binding
protein; TNFα, tumor necrosis factor α; UPR, unfolded protein response; XBP1, X-box binding protein 1.
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FIGURE 1 | Schematic representation of the structure and functions of SND1 protein. The protein comprises a tandem of four Staphylococcal nuclease-like domains
(SN1-4) followed by a fusion of an entire Tudor domain and a truncated SN domain (SN5). SN and Tudor domains enable SND1 for interacting with RNA/DNA and
proteins to operate in a plethora of processes.
transcription factors, including EBNA2 (5, 14), c-Myb (15),
STAT6 (16), STAT5 (17), E2F1 (18), and PPARγ (19).
Moreover, the SND1-mediated post-transcriptional regulation is
surprisingly diverse. It includes spliceosome assembly and pre-
mRNA splicing (20, 21), RNA interference, stability and editing
(6, 9, 10), microRNA (miRNA) decay (22), and RNA protection
in stress granules (23, 24). In addition, it has been illustrated a role
for SND1 in the regulation of protein synthesis, ubiquitination
and proteasomal degradation (25, 26).
Clinical and experimental studies show a close association
between overexpression of SND1 and progression and
aggressiveness of a spectrum of common cancers that include
colon, breast, prostate, lung, glioma, melanoma, and liver cancer
(27–34). Using different models, researchers have identified a
host of mechanisms through which SND1 modulates prosurvival
and proliferative genes promoting carcinogenesis. Of particular
relevance are the networks involving NF-κB activation and
miR-221 induction (32), miR-184 expression and JAK/STAT3
inhibition (34), TGFβ1/Smad signaling pathway (25), Wnt/β-
catenin activation (27), ERK, and Akt activation (35, 36), as
well as the interaction of SND1 with partner proteins like
metadherin-1 (30, 37) and monoglyceride lipase (26).
Since full or organ-selective SND1-knockout animal models
are not yet available, the systemic role of SND1 remains to
be fully delineated. Several works have shown that knocking
down endogenous SND1 inhibits proliferation in diverse cancer
cell lines (23, 29, 37–39). As physical interaction of SND1
with E2F1 is critical for the G1/S phase transition (18), the
cell cycle arrest in SND1-knockout cells has been attributed to
the absence of the SND1-driven endonucleolytic degradation of
specific miRNAs that downregulate crucial proteins for the G1/S
transition, including E2F1 (18, 40). In addition, other studies
have reported that SND1 knockdown fosters apoptosis (41),
reduces RISC activity (29, 37), and impairs the aggregation of
stress granules (23).
The oncogenic functions assigned to SND1 might be also
regarded as a result of its ubiquitous expression in tissues (42) and
its ample capacity for interacting with nucleic acids, individual
proteins, and protein complexes in the cytoplasmic (43–45) and
nuclear compartments (46). Consistent with this, we recently
documented that, in human hepatoma HepG2 cells, nuclear
SND1 interacted with the genomic DNA to hook SND1 on the
promoter of a broad number of target genes modulating cell
growth, oncogenic transformation, viral infection and metabolic
regulation (47).
Extensive rewiring of lipid metabolism and lipogenic
phenotypes are features that distinguish cancer cells from
normal cells (48, 49). Besides providing energy and building
units for the newly forming cells, lipids generate a network
of protumorigenic signals that promote tumor growth (49).
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Strong evidence support a role for SND family members in
lipid homeostasis. Particularly illustrative are their implication
on specific aspects of lipid bodies biogenesis and the secretion
of milk lipids by mammary epithelial cells (43, 50), the secretion
of lipoprotein particles by liver parenchymal cells (45, 51),
and the expression of genes regulating glycerophospholipid
homeostasis and phosphatidylcholine content in HepG2 cells
during inflammation (47). Interestingly, recent findings have
revealed that SND1 overexpression alters cholesterogenesis and
limits triglyceride synthesis via modulation of the regulatory
cholesterol pool in endoplasmic reticulum, thus suggesting that
SND1 may be decisive to determine events that modify the
permeability properties of cancer cell membranes and facilitate
cell proliferation (52, 53).
Despite these and other major advances, the precise
function of SND1 in normal and challenged cells is not fully
clarified. SND1 function and SND1 transcription regulation
are inseparable. Nevertheless, as is often the case, there is a
surprisingly limited knowledge of themolecular mechanisms and
agents that regulate SND1 production at the transcription level
under the above-mentioned pathophysiological conditions.
After briefly summarizing the SND1 genomic context, the
present review will mainly focus on the human SND1 promoter
characterization. We provide a comprehensive description of
the transcription factors and signal transduction pathways that
trigger SND1 promoter activation in different cell types and
conditions.
THE HUMAN SND1 GENE
Orthologues of SND1 are found in mammals (5, 14, 54), plants
(4), Drosophila, C. elegans (9), and many other species. The
main characteristics of the gene, transcript, protein and gene
promoter for Homo sapiens and for the two most common
rodents Mus musculus and Rattus norvegicus are shown in
Table 1. The genomic context of human SND1 is the large
arm of the chromosome 7 (7q32.1), while Snd1 is assigned to
chromosome 4 (4q23) in the rat (55) and to chromosome 6 in
the mouse. It is worth mentioning that the large arm of human
chromosome 7 is associated with chromosomal instability and
many types of neoplasia (56).
The human and rodent genes expand 400-455 kb and contain
24 exons with identical organization, and conserved intron-exon
boundary sequences in agreement with the canonical GT/AG
rule. The transcription initiation site of the human gene was
mapped at exon 1, while the rat Snd1 gene pointed to the
existence of two different transcription start sites, the main
one being assigned to the G at position 216 upstream of the
ATG codon and the secondary start point 34 bp downstream
(57). SND1 encodes 16 splicing variant transcripts, one of
them translates into the full SND1 protein of 910 amino
acids, other codes for a 231 amino acid protein shortened
in the two extremes -uncharacterized- and the others are
noncoding transcripts. The mouse and rat Snd1 proteins contain
910/909 amino acids, respectively. Sequences are 90% identical
TABLE 1 | General information of SND1 gene, transcript, protein and promoter in humans, mouse and rat.
Homo sapiens
(human)
Mus musculus
(house mouse)
Rattus norvegicus
(Norway rat)
Gene name SND1 Snd1 Snd1
Gene ID ID: 27044 ID: 56463 ID: 64635
Aliases TDRD11, Tudor-SN, p100 AL033314, Tudor-SN SND p102
Chromosome 7 6 4
Location NC_000007.14
(127651989..128092609)
NC_000072.6
(28480315..28935162)
NC_005103.4
(55772377..56171669)
Length (bases) 440,621 454,848 399,293
% Identity vs. human 87 84
Exon counts 24 24 24
mRNA ID NM_014390.3 NM_019776.2 NM_022694.2
Length (bases) 3,678 3,482 3,475
% Identity vs. human 87 87
Protein ID NP_055205.2 NP_062750.2 NP_073185.2
Aminoacids (number) 910 910 909
% Identity vs. human 97 97
Promoter EF690304 - AY957585
Length (bases) 3,808 4,600 1,688
% Identity vs. human, Region (−300, +20) 82 84
CpG island 904 bp (−555, +349) 850 bp (−532, +318) 912 bp (−394, +518)
G-quadruplex (number), Region (−300, +20) 4 2 3
Data are extracted from https://www.ncbi.nlm.nih.gov/ database and analyzed using BLAST, UCSC Genome Browser (Dec 2013 GRCh38/hg38) and GQRS Mapper tools.
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between human, rat and mouse genes and reach 97.4% for the
proteins.
The genomic landscapes of the three orthologues are
partially similar (Figure 2). Upstream, antisense PAX4 and
sense FSCN3 and, downstream, sense miR-129-1 are conserved.
Complexity of intragenic elements is far greater in the human
compared with the murine genes. Although LRRC4, a gene
involved in the normal development and tumorigenesis of the
nervous system, is shared by the three orthologues in antisense
orientation, there are two overlapping intronic elements in the
same strand orientation as the host gene that are unique to
human SND1: miRNA-593 and the SND1 intronic transcript
1 (SND1-IT1). These elements map at introns 17 and 16,
respectively.
Despite being defined as a long noncoding RNA gene,
SND1-IT1 has the capacity of encoding an uncharacterized
protein called brain and nasopharyngeal carcinoma susceptibility
protein NAG8. Low levels of a different noncoding intronic
transcript derived from SND1 have been detected in clear cell
renal carcinoma (58). This novel transcript maps at the yet
uncharacterized intron 14.
Using the genomic resources miRBase and Ensembl, Godnic
et al. identified 27 miRNA/host gene pairs with cross-species
conserved location (59). Among them, the pair miRNA-
593/SND1 is of particular interest for being a miRNA gene
located within a gene encoding for a component of the miRNA
silencing machinery. The miR-593 gene has been linked to
certain diseases, including breast cancer (60), esophageal cancer
(61), and pediatric medulloblastoma (62), and is considered a
non-invasive diagnostic biomarker for children with combined
pituitary deficiency (63). Likewise, Fan et al. demonstrated a role
for the BRCA1-mir-593-5p-MFF axis in cisplatin sensitivity in
tongue squamous cell carcinoma (64).
Whether transcription initiation regions of intragenic
miRNAs are into or separate from the promoter of their host
genes is a matter under intense study. Approximately 50%
of the intragenic miRNAs are known to be expressed from
the introns of their host genes (65), whereas about one-third
of the intronic miRNAs have transcription initiation sites
different from the host gene promoter (66). Intriguingly,
the miRNA-593-5p is an intronic miRNA in the SND1 gene
whose BRCA1 binding site is within the SND1 gene sequence
(64). In analyzing the 5-kb region upstream of miR-593-5p,
Fan et al. found that BRCA1 transactivated indeed miR-593-
5p expression increasing its promoter activity. By contrast,
they observed that BRCA1 overexpression failed to alter
substantially SND1 mRNA levels (64), suggesting that this
miRNA/host gene pair does not share the transcription start
sites.
THE SND1 PROMOTER
Understanding a protein-coding gene promoter not only
provides a deep insight into the regulation of gene expression
but also sheds light on the protein function. We will review the
current knowledge available on the SND1 promoter architecture
and the set of transcription factors that bind the proximal
promoter. We also describe an in silico analysis of the quadruplex
forming G-rich sequences that could alter SND1 promoter shape
and activity.
Basal SND1 Expression
Our own previous studies provided the isolation and
characterization of a 3,808 bp sequence of the human SND1
gene promoter (GenBank ID: EF690304) (67), and a region of
1,688 bp corresponding to the rat Snd1 promoter (GenBank
ID: AY957585) (57). Comparing the Homo sapiens and Rattus
Norvegicus genome databases we found 84% identity in a 300 bp
region upstream to the transcription start point of the isolated
promoter sequences of SND1 (Table 1). Similar identity (82%)
was found in the same region of the 5′ flanking region of the
mouse Snd1 (Table 1). The high sequence similarities between
FIGURE 2 | Genomic regions for the human SND1 and the rat and mouse orthologues. Contexts are well conserved in the three species regarding PAX4, FCSN3 and
Mir129-1. The SND1 gene hosts LRRC4 while the intronic genes MIR593 and SND1-IT1 (SND1-intronic transcript 1) are present only in the human genome in sense
orientation.
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species point to the presence of conserved pattern of cis-elements
that are critical for the protein expression regulation along
evolution.
Bioinformatic analysis of the promoter sequences revealed
multiple cis-acting elements and potential binding motifs for
transcription factors relevant in regulating SND1 transcription
under basal and activated cellular states. We identified features
characteristic of housekeeping genes, such as the absence of
the canonical TATA box and the presence of CCAAT boxes
and a large number of GC-sites (57, 67, 68). Most TATA-less
promoters are enriched in CpG islands and CCAAT boxes near
the transcription start site in specific locations for recruiting
and stabilizing the transcriptional machinery. Human and rat
gene promoters possess one CpG island in the region (−555,
+349) and (−394, +518) respectively, with multiple GC boxes
for the functional binding of Sp1 transcription factor (67, 68).
Both promoters also contain two reverse CCAAT boxes, common
elements in the eukaryotic genes that usually appear in the
(−80, −40) region of promoters with or without TATA box
(69). We demonstrated that these motifs are binding sites for
NF-Y by using immunoprecipitated chromatin from human
and rat hepatoma cells (57, 67, 68). Therefore, every one of
the CCAAT boxes and GC boxes are regulatory elements likely
required to maintain the basal expression of SND1 in most
tissues.
Promoter activity of 5′-deletion fragments determined by
luciferase reporter assays in human and rat hepatoma cells
revealed a minimal promoter at−112 bp and an enhancer region
between −112 and −274 bp that accounted for the maximal
transcriptional activity of the proximal promoters (67, 68). As
Figure 3A shows, this region contains two CCAAT boxes at
position −28 and −61 in the human promoter and six GC
boxes conserved in the rat homologue that are recognized by
NF-Y and Sp1 and assess the efficient transcription of the SND1
gene family. Functionality of these elements was confirmed in
mutation experiments (67, 68).
Regulatory Elements Associated With
SND1 Expression
Beyond the conserved cis-elements in SND1 proximal promoter,
we characterized a number of regulatory elements that control
SND1 promoter activity in adaptation to cell environment
changes. These elements receive inputs from a multitude of
stimuli and signaling pathways through a customized collection
of transcription factors that might affect SND1 expression.
Emerging information from plants (4) and animal cells has
demonstrated that SND1 protein expression changes in response
to cellular stresses related to inflammation, tumor growth,
hypoxia, heat shock, oxidative conditions, and DNA damage
(12, 70, 71).
Cellular stress results in an inflammatory response mainly
triggered by inflammatory cytokines such as TNFα and
mediated by the activation of NF-κB cascade. NF-κB is the key
transcription factor that induces the expression of protective
genes and finally resolves the protection or death of the cell
(72, 73). We reported the activation of SND1 transcription and
the nucleocytoplasmic redistribution of SND1 protein during the
inflammatory response prompted by TNFα in human hepatoma
cells (47, 67). Upregulation of SND1 involved direct binding of
NF-κB to five target sites in the proximal promoter, as shown
in Figure 3A (67). This response seems to be human-specific,
as, although the NF-κB binding site motif is conserved in the
rat promoter, NF-κB did not interact with that region. Whether
SND1 displays a protective role for liver cells under inflammatory
conditions is an intriguing possibility that warrants future in-
depth studies.
Inflammation is linked to endoplasmic reticulum (ER) stress
through a crosstalk between NF-κB, ATF6 and XBP1 signaling
pathways (74). In response to ER stress, eukaryotic cells
trigger various signaling cascades termed the unfolded protein
response (UPR) for controlling gene transcription and switching
off translation initiation. Non-translating cellular mRNAs are
sequestered into cytoplasmic stress granules waiting for a later
translation or degradation (75). In this sense, it is worth
mentioning that SND1 has been defined as an important protein
in RNA protection due to its ability to interact with protein
components of the cytoplasmic stress granules (12, 23, 24, 70, 71,
76). We presented experimental data of SND1 protein expression
and SND1 promoter activity upregulation by pharmacological ER
stress in HepG2 cells (77). We encountered a number of potential
ER stress response elements in SND1 promoter and by plasmid-
mediated ATF6 overexpression demonstrated the participation
of the transcription factor ATF6 in the transcriptional activation
of SND1 gene (77). ATF6 is a membrane-bound transcription
factor that plays a central role in the UPR. When agents
disrupt the folding of proteins in the ER, ATF6 is cleaved by
sequential proteolysis to release its cytoplasmic domain, which
enters the nucleus and activates protective gene transcription.
Therefore, SND1 can be added to the selective list of ATF6 target
genes.
Given that the cellular processing of ATF6 activation is
analogous to that undergone by sterol regulatory element binding
proteins (SREBPs) in response to cholesterol deprivation, parallel
activation of ATF6 and SREBP-2 in animal cells (78) may be
envisioned.
In this regard, our own work revealed that SND1 is a
target gene for SREBPs. The activation of SREBP-2 in HepG2
cells cultured in the presence of the cholesterol synthesis
inhibitor simvastatin or in a lipoprotein-deficient medium
resulted in an increment of SND1 promoter activity and
transcript levels (79). ChIP and mutational assays confirmed
the functional binding of SREBP-2 to two sites in the proximal
promoter sequence containing the SRE −60 and E-box −230
motifs while SREBP-1 binding is restricted to the region with
the regulatory element SRE −60 (Figure 3B). SREBP-gain-
of function and loss-of function experiments confirmed the
binding of endogenous SREBP-2 and SREBP-1 to specific sites
on the SND1 promoter. To our surprise, binding regulated
SND1 transcription in opposite ways: induction by SREBP-2 and
repression by SREBP-1 overexpression (79). Such contrasting
effects suggest that SND1 expression responds to particular
upstream signals recruiting selectively SREBP-1 and/or SREBP-
2 in concert with a set of transcription factors to SND1
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FIGURE 3 | Location of key regulatory elements of the human SND1 proximal promoter. (A) Diagram of region (-400, +10) of the promoter. Promoter activity is under
the control of the transcription factors Sp1, NF-κB and NF-Y with 11 (GC boxes, red and white ovals), 5 (NF-κB elements, blue ovals) and 2 (CCAAT boxes, gray and
white diamonds) binding sites identified, respectively. The rat promoter conserves some of these regulatory sites. (B) Promoter activity is increased by SREBP-2
binding to E-box −230 and/or SRE −60 whereas it is inhibited by SREBP-1 binding to SRE −60. The arrow indicates the transcription initiation site.
promoter. We now know that the optimal action of SREBPs
usually requires the cooperation with other transcription factors,
commonly Sp1 and NF-Y (80). The promoter of SND1 contains
conserved sites for Sp1 and NF-Y quite close to SRE −60.
Preliminary findings indicate that, whereas the SREBP-2-driven
activation of SND1 promoter is independent of Sp1 and/or
NF-Y, the participation of NF-Y is required for the inhibition
of the SND1 promoter activity by SREBP-1 (79). Contribution
of SND1 and SREBPs to lipid metabolism reprogramming in
cancer cells may be, otherwise, expected in view of the report
illustrating that deregulated cholesterol homeostasis and SREBP-
2 activity is associated with SND1 overexpression (52). We need
to keep in mind that this setting facilitated hepatic cancer cell
proliferation.
A recent study reported a close association between SND1
upregulation and TGFβ1/Smad signaling pathway activation in
order to promote epithelial-to-mesenchymal transition in breast
cancer (25). Mechanistically, TGFβ1 triggers the activation of
Smads’ transcription factors and the Smad2/Smad3 complex
binds specific recognizing sites located in the distal promoter
of SND1 at region (−1,100, −1,000) and (−2,100, −2,000)
and enhances the transcriptional activity (25) (Figure 4). The
downstream action of SND1, functioning as a coactivator,
finally results in the disruption of cytoskeletal organization and
increased cell motility and invasion and metastasis of breast
cancer.
Evidence of a direct binding of c-Myb to the promoter of
human SND1 has been provided by ChIP-on-chip assays (81). c-
Myb is a key transcription factor in proliferation, differentiation,
and cell survival. It is activated in certain human leukaemias
and in solid cancers such as colon and breast cancer (82).
In breast cancer, c-Myb interacts with transcriptional cofactors
and binds to E-box and c-myb sites on the gene promoters
to activate their transcription (83). By similarity, it is tempting
to speculate that c-Myb may recognize certain E-box motifs
within the promoter sequence of SND1 and modulate the
transcription of the gene. Nevertheless, the regulatory role of
c-Myb over SND1 promoter activity, if any, remains to be
confirmed.
The ensuing conclusion is that SND1 expression is modulated
by growth factors, inflammatory cytokines, ER disruptors, and
metabolic stress, all signals addressed by the transcription factors
Smads, NF-κB, ATF6, and SREBPs, and other factors still to
enumerate (Figure 4). Altogether, these findings suggest the
involvement of SND1 in diverse pathways that are dysregulated
in oncogenic processes. In other words, cells handle external
stimuli that condition the outputs and the program of factors
and cofactors that modulate the SND1 promoter activity and
the level of expression of SND1. Setting the level of SND1
is crucial. A more comprehensive insight into regulation
of SND1 transcription will require understanding how the
cis- and trans-regulatory elements work as a unit in the
promoter.
Alternative DNA Conformations Affecting
SND1 Expression
A corollary of the above is that some aspects of gene
expression are under the control of transcription factors and
cis-acting elements in the gene promoter region in a highly
dynamic manner. In addition, features beyond the primary
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FIGURE 4 | Scheme illustrating the signaling pathways and transcription factors contributing to SND1 promoter activation. SND1 is transcriptionally upregulated by
several stress settings, including TGF/Smads pathway through Smad2/3 binding, NF-κB-mediated inflammation, SREBP activation concomitant to cholesterol
depletion and ATF6/XBP1-mediated endoplasmic reticulum stress.
sequence of DNA, including DNA shape and flanking sequences,
can modulate binding specificity of a transcription factor to
distinct sites (84). For instance, DNA sequences enriched in
GC are susceptible to adopting non-B-DNA conformations
such as single-stranded DNA and G-quadruplex structures. An
intriguing observation is the significant enrichment of DNA
G-quadruplex-forming motifs in most oncogene promoters (85).
A G-quadruplex is a four-stranded DNA structure that is
composed of stacked guanine tetrads linked by loop nucleotides
that can differ in their folding patterns (86). The heterogeneity
of G-quadruplex structures and the potential therapeutic
applications as targets for antitumor drugs have attracted intense
attention during the last years (87–89). Thus, identification
of G-quadruplex structures in human genes is continuously
growing. G-quadruplexes in promoter regions act as important
modulators of transcriptional regulation and can activate or
repress gene expression (89, 90). As SND1 is considered an
oncogene, we interrogated SND1 promoter for the possibility of
G-quadruplex structures. Here we report the findings for the first
time.
A set of in silico algorithms are available for predicting G-
quadruplex structures in DNA or RNA nucleotide sequences. By
using the web-based server QGRS Mapper (91) and QuadBase2
(92) we found the potential to form four G-quadruplex structures
in the SND1 proximal promoter (Figure 5A and Table 1). One
exclusive sequence found at −51 in the proximal promoter of
SND1, but not in the rat and mouse orthologues, was the best
candidate to form a stable G-quadruplex structure according to
the high computed scoring. The predicted structures occur in
a DNAse I hypersensitivity peak located at (−287, +3) by the
ENCODE group at UCSC Genome Browser (GRCh38/hg38).
In general, nuclease hypersensitive sites provide information
about the active transcriptional regulatory elements (93). It
is particularly interesting that, in this GC-rich region, there
are placed various conserved GC boxes recognized by Sp1
(Figure 3A). Whether G-quadruplexes formation masks some
specific Sp1 binding sites or, instead, it confers a new binding
site for an alternative factor onto SND1 promoter and their
consequences on SND1 expression require further in-depth
studies.
Figure 5B shows that there are also several putative G-
quadruplex forming motifs in the 3′ UTR sequence of the SND1
transcript. G-quadruplex structures might affect miRNA binding
sites and, therefore, alter SND1 mRNA posttranscriptional
processing.
Again, there is limited information relative to the
posttranscriptional regulation of SND1 gene. We know that
SND1 mRNA is modulated by microRNAs. Of particular clinical
interest is the identification of miR-361-5p, miR-184 and miR-
320a targeting the 3′ UTR of the SND1 transcript. It has been
illustrated that overexpression of either miR-361-5p, miR-184, or
miR-320a decreased cancer cell viability, migration and invasion
through direct downregulation of SND1 oncogene in gastric and
colorectal cancer (94), in malignant glioma and breast cancer
(34, 95) and in lung cancer cells (96). These findings rise the
question about the diagnostic relevance of these miRNA/SND1
axes and their therapeutic application as a tumor suppressive
strategy for cancer treatment.
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FIGURE 5 | Predicted G-quadruplex structures in the SND1 proximal promoter and the 3′UTR sequence. In silco prediction and distribution of the quadruplex forming
G-rich sequences (each G-group in boxes) found by QGRS Mapper program (91) in the nucleotide sequence of human SND1 promoter (A) and 3′ untranslated
region (B).
CONCLUSIONS AND FUTURE
PERSPECTIVES
We are currently lacking a thorough examination about the
precise role of SND1 in normal and challenged cells. A
detailed map of the SND1 transcriptional regulation is needed.
Here we illustrate the promoter architecture of SND1 and
the set of transcription factors that modulate the promoter
activity and the level of transcription of SND1. It is relevant
that SND1 expression is under the control of transcription
factors, such as NF-Y, Sp1, Smads, NF-κB, ATF6, and SREBPs,
which operate in a number of physio-pathological molecular
mechanisms. Given the close connection of SND1 with the
control of cell growth and malignant transformation, SND1
has become a novel candidate for cancer treatment and a
valid molecular biomarker for prognosis and diagnosis in some
cancers (32, 37, 38, 97). The inhibition of SND1 gene and
SND1 protein is at present the focus of a number of clinical
investigations.
A selective inhibitor of the SND1 endonuclease activity, the
3′5′-deoxythymidine bisphosphate, has succeeded in reducing
hepatocellular carcinoma cells proliferation and inflammation, as
well as in vivo tumor formation (36, 37). This inhibitor might
serve as a specific nontoxic antitumor agent as it impairs the
enzymatic activity-driven functions of SND1 but is ineffective
against those that are nuclease-independent. Viable options to
investigate the effect of SND1 inhibition in overcoming cancer
progression are SND1 targeting by nanoparticles-encapsulated
specific siRNAs (98) as well as the generation of full or
conditional SND1 knockout mouse models. These approaches to
SND1 deletion would provide an overview about the biological
significance of SND1 and its involvement in oncogenic processes
and normal development.
Aforementioned findings about the SND1 promoter
regulation may have implications in the development of
therapeutic interventions capable of acting on the transcription
of SND1 gene directly. Regulatory elements and transcription
factors that transcriptionally upregulate SND1 are commonly
involved in oncogenic processes. Their inhibition by genome
editing or drugs exerts solid antitumor effects (99, 100). An
important question to address is how the inhibition of each
transcription factor can affect the oncogenic functions of SND1
and whether their combination with SND1 endonuclease
inhibitors may offer clinical benefits.
A particularly promising aspect to challenge as potential
targets to downregulate SND1 overexpression in tumor cells
is the potential presence of functional G-quadruplex forming
motifs in the promoter region of SND1. A variety of small ligands
have been reported to induce the formation and stabilization of
G-quadruplex structures in most oncogenes andmight be used as
anti-cancer drugs (87, 88). However, whether the G-quadruplex
structures in the DNA may have a role, either inhibitory or
activatory, in the control of SND1 expression is unknown and
a hypothesis that needs to be interrogated.
In conclusion, the functional diversity of SND1 marks
this gene as interesting for further analysis in relation with
the multiple levels of regulation of SND1 protein expression.
Analysis of SND1 orthologues using approaches such us gene
overexpression, silencing, mutant analysis, transgenic and organ-
specific knockout animals, could help to elucidate the role of
SND1 in normal cell growth, development and oncogenesis,
and to assess whether the distorted SND1 expression level is
the cause or the consequence of the oncogenic environment.
This does not rule out the possibility that the encoded protein
SND1 has protective roles throughout a series of effectors in
cells undergoing certain stress types. The reported findings show
features supporting both sides of the coin.
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